Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAGNASDAQ:AQSTNASDAQ:ARCTNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.41+0.7%$1.80$1.33▼$3.58$65.72M0.6160,140 shs2,559 shsAQSTAquestive Therapeutics$2.38-7.9%$2.91$2.20▼$5.80$234.82M2.591.59 million shs475,102 shsARCTArcturus Therapeutics$8.79-10.5%$14.14$8.04▼$45.00$242.18M3.41458,237 shs207,796 shsSLDBSolid Biosciences$2.61-4.9%$4.39$2.48▼$11.28$202.57M2.07875,402 shs306,993 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-3.45%-14.63%-29.65%-28.21%-53.18%AQSTAquestive Therapeutics+8.86%-15.13%+1.57%-17.57%-36.92%ARCTArcturus Therapeutics+10.21%-3.73%-31.28%-48.18%-68.98%SLDBSolid Biosciences+2.62%-25.75%-46.17%-32.01%-76.30%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAGAdagene2.2524 of 5 stars3.33.00.00.02.61.70.6AQSTAquestive Therapeutics1.6342 of 5 stars3.62.00.00.03.40.00.0ARCTArcturus Therapeutics2.8086 of 5 stars4.60.00.00.01.62.51.3SLDBSolid Biosciences3.3862 of 5 stars3.72.00.00.02.94.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.50Moderate Buy$8.00467.38% UpsideAQSTAquestive Therapeutics 3.13Buy$10.57345.11% UpsideARCTArcturus Therapeutics 3.13Buy$59.20573.88% UpsideSLDBSolid Biosciences 3.33Buy$15.67501.41% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, ARCT, AQST, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/3/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/13/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $11.003/10/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.003/10/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/10/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $68.003/10/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $20.003/7/2025AQSTAquestive TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$7.003/7/2025AQSTAquestive TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/7/2025AQSTAquestive TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$103.20K643.63N/AN/A$1.61 per share0.88AQSTAquestive Therapeutics$57.56M4.08N/AN/A($1.59) per share-1.49ARCTArcturus Therapeutics$138.39M1.72N/AN/A$10.42 per share0.84SLDBSolid Biosciences$8.09M24.95N/AN/A$6.27 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$18.95MN/A0.00N/AN/AN/AN/AN/AN/AAQSTAquestive Therapeutics-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%5/6/2025 (Estimated)ARCTArcturus Therapeutics-$29.73M-$3.01N/AN/AN/A-36.39%-22.39%-14.81%5/6/2025 (Estimated)SLDBSolid Biosciences-$96.01M-$3.04N/AN/AN/AN/A-58.75%-47.84%5/13/2025 (Estimated)Latest ADAG, ARCT, AQST, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025AQSTAquestive Therapeutics-$0.17N/AN/AN/A$12.23 millionN/A3/6/2025Q4 2024ARCTArcturus Therapeutics-$0.33-$1.11-$0.78-$1.11$44.64 million$22.77 million3/5/2025Q4 2024AQSTAquestive Therapeutics-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AARCTArcturus Therapeutics$0.718.14%N/AN/A N/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.082.50N/AAQSTAquestive TherapeuticsN/A6.375.91ARCTArcturus TherapeuticsN/A4.764.76SLDBSolid BiosciencesN/A7.857.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%AQSTAquestive Therapeutics32.45%ARCTArcturus Therapeutics94.54%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%AQSTAquestive Therapeutics7.85%ARCTArcturus Therapeutics15.30%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.11 million34.89 millionNot OptionableAQSTAquestive Therapeutics16098.87 million84.02 millionOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableSLDBSolid Biosciences10077.49 million35.05 millionOptionableADAG, ARCT, AQST, and SLDB HeadlinesRecent News About These CompaniesSolid Biosciences Inc. (NASDAQ:SLDB) Receives $15.67 Average Price Target from AnalystsApril 10 at 2:07 AM | americanbankingnews.comSolid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by ADAR1 Capital Management LLCApril 9 at 7:13 AM | marketbeat.comSolid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy SpaceApril 8 at 5:06 PM | seekingalpha.comCan Solid Biosciences Challenge Sarepta in the DMD Market?April 8 at 7:30 AM | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Average Rating of "Buy" from AnalystsApril 8 at 2:06 AM | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading Down 7.9% - Time to Sell?April 6, 2025 | marketbeat.comSolid Biosciences reports inducement grants under Nasdaq listing ruleApril 2, 2025 | markets.businessinsider.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comWhy Solid Biosciences Inc.’s (SLDB) Stock Is Down 14.97%April 1, 2025 | aaii.comTruist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB)March 21, 2025 | markets.businessinsider.comSolid Biosciences Inc. (SLDB): Among Top Insider Purchases Last MonthMarch 14, 2025 | insidermonkey.comJPMorgan Chase & Co. Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock PriceMarch 14, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Stock Price Up 0.5% - Still a Buy?March 13, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of "Buy" from BrokeragesMarch 13, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateMarch 13, 2025 | marketbeat.comSolid Biosciences (SLDB) Receives a Buy from J.P. MorganMarch 12, 2025 | markets.businessinsider.comSolid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 12, 2025 | globenewswire.comEquities Analysts Offer Predictions for SLDB Q1 EarningsMarch 12, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading Down 4.9% - What's Next?March 11, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Shares Down 3.1% - Here's What HappenedMarch 11, 2025 | marketbeat.comSolid Biosciences price target raised to $20 from $16 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military Spending3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialCan Solid Biosciences Challenge Sarepta in the DMD Market?By Leo Miller | April 8, 2025View Can Solid Biosciences Challenge Sarepta in the DMD Market?ADAG, ARCT, AQST, and SLDB Company DescriptionsAdagene NASDAQ:ADAG$1.41 +0.01 (+0.71%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Aquestive Therapeutics NASDAQ:AQST$2.38 -0.21 (-7.95%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Arcturus Therapeutics NASDAQ:ARCT$8.78 -1.04 (-10.54%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Solid Biosciences NASDAQ:SLDB$2.60 -0.14 (-4.93%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
